Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1 and ATM mutations in chronic lymphocytic leukemia

Research output: Contribution to journalArticle

Authors

  • Ferran Nadeu
  • Julio Delgado
  • Cristina Royo
  • Tycho Baumann
  • Magda Pinyol
  • Pedro Jares
  • Alba Navarro
  • David Martín-García
  • Sílvia Beà
  • Itziar Salaverria
  • Marta Aymerich
  • Helena Suárez-Cisneros
  • Maria Rozman
  • Neus Villamor
  • Dolors Colomer
  • Armando López-Guillermo
  • Marcos González
  • Miguel Alcoceba
  • Maria José Terol
  • Enrique Colado
  • Xose S Puente
  • Carlos López-Otín
  • Anna Enjuanes
  • Elías Campo

Colleges, School and Institutes

Abstract

Genomic studies have revealed the complex clonal heterogeneity of chronic lymphocytic leukemia (CLL). The acquisition and selection of genomic aberrations may be critical to understand the progression of this disease. In this study we have extensively characterized the mutational status of TP53, SF3B1, BIRC3, NOTCH1 and ATM in 406 untreated CLL cases by ultra-deep next-generation sequencing, which detected subclonal mutations down to 0.3% allele frequency. Clonal dynamics was examined in longitudinal samples of 48 CLL patients. We identified a high proportion of subclonal mutations, isolated or associated with clonal aberrations. TP53 mutations were present in 10.6% of patients (6.4% clonal, 4.2% subclonal), ATM mutations in 11.1% (7.8% clonal, 1.3% subclonal, 2% germline mutations considered pathogenic), SF3B1 mutations in 12.6% (7.4% clonal, 5.2% subclonal), NOTCH1 mutations in 21.8% (14.2% clonal, 7.6% subclonal), and BIRC3 mutations in 4.2% (2% clonal, 2.2% subclonal). ATM mutations, clonal SF3B1 and both clonal and subclonal NOTCH1 mutations predicted for shorter time to first treatment (TTT) irrespective of the IGHV mutational status. Clonal and subclonal TP53 and clonal NOTCH1 mutations predicted for shorter overall survival together with the IGHV mutational status. Clonal evolution in longitudinal samples mainly occurred in cases with mutations in the initial samples and was observed after chemotherapy but also in untreated patients. These findings suggest that the characterization of the subclonal architecture and its dynamics in the evolution of the disease may be relevant for the management of CLL patients.

Details

Original languageEnglish
JournalBlood
Early online date2 Feb 2016
Publication statusE-pub ahead of print - 2 Feb 2016